Innovative Platform Genosco's proprietary G-SMART™ platform enables targeted discovery based on rare protein kinase sequences, positioning the company at the forefront of precision medicine in the biotech industry.

Growing Pipeline With a lead candidate, Lazertinib, currently in phase 3 clinical trials and partnered with Janssen, there are significant opportunities to offer clinical insights, companion diagnostics, and support services throughout the drug development lifecycle.

Strategic Partnerships Genosco's collaboration with Yuhan Corporation for Lazertinib underscores potential for co-marketing, development collaborations, and licensing opportunities in large markets such as Korea and beyond.

Recent IPO Status Having gone public recently, Genosco may require advanced financial, data analytics, and compliance solutions to support its growth plans and investor reporting activities.

Market Expansion Genosco’s focus on unmet medical needs and precision treatments creates opportunities to engage in targeted sales initiatives, including partner solutions in clinical data management, research analytics, and healthcare IT systems.